These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24386644)

  • 61. Therapeutic application of GPR119 ligands in metabolic disorders.
    Yang JW; Kim HS; Choi YW; Kim YM; Kang KW
    Diabetes Obes Metab; 2018 Feb; 20(2):257-269. PubMed ID: 28722242
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Differential anti-diabetic effects and mechanism of action of charantin-rich extract of Taiwanese Momordica charantia between type 1 and type 2 diabetic mice.
    Wang HY; Kan WC; Cheng TJ; Yu SH; Chang LH; Chuu JJ
    Food Chem Toxicol; 2014 Jul; 69():347-56. PubMed ID: 24751968
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.
    McKillop AM; Moran BM; Abdel-Wahab YH; Gormley NM; Flatt PR
    Diabetologia; 2016 Dec; 59(12):2674-2685. PubMed ID: 27677765
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists.
    Matsuda D; Kawamura M; Kobashi Y; Shiozawa F; Suga Y; Fusegi K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
    Bioorg Med Chem; 2018 May; 26(8):1832-1847. PubMed ID: 29486951
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
    Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
    J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
    [TBL] [Abstract][Full Text] [Related]  

  • 66. GPR119 as a fat sensor.
    Hansen HS; Rosenkilde MM; Holst JJ; Schwartz TW
    Trends Pharmacol Sci; 2012 Jul; 33(7):374-81. PubMed ID: 22560300
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antidiabetic effect of total flavonoids from Sanguis draxonis in type 2 diabetic rats.
    Chen F; Xiong H; Wang J; Ding X; Shu G; Mei Z
    J Ethnopharmacol; 2013 Oct; 149(3):729-36. PubMed ID: 23933499
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor.
    Ansarullah ; Lu Y; Holstein M; DeRuyter B; Rabinovitch A; Guo Z
    PLoS One; 2013; 8(1):e53345. PubMed ID: 23382843
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo.
    Huan Y; Jiang Q; Li G; Bai G; Zhou T; Liu S; Li C; Liu Q; Sun S; Yang M; Guo N; Wang X; Wang S; Liu Y; Wang G; Huang H; Shen Z
    Sci Rep; 2017 Jun; 7(1):4351. PubMed ID: 28659588
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.
    Katz LB; Gambale JJ; Rothenberg PL; Vanapalli SR; Vaccaro N; Xi L; Sarich TC; Stein PP
    Diabetes Obes Metab; 2012 Aug; 14(8):709-16. PubMed ID: 22340428
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The significance of GPR119 agonists as a future treatment for type 2 diabetes.
    Dhayal S; Morgan NG
    Drug News Perspect; 2010 Sep; 23(7):418-24. PubMed ID: 20862393
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Insulinotropic action of 2, 4-dinitroanilino-benzoic acid through the attenuation of pancreatic beta-cell lesions in diabetic rats.
    Jahan H; Choudhary MI; Manzoor M; Khan KM; Perveen S; Atta-Ur-Rahman
    Chem Biol Interact; 2017 Aug; 273():237-244. PubMed ID: 28625491
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats.
    Chang AY; Wyse BM; Gilchrist BJ; Peterson T; Diani AR
    Diabetes; 1983 Sep; 32(9):830-8. PubMed ID: 6354790
    [TBL] [Abstract][Full Text] [Related]  

  • 75. GPR119 agonists 2009-2011.
    Buzard DJ; Lehmann J; Han S; Jones RM
    Pharm Pat Anal; 2012 Jul; 1(3):285-99. PubMed ID: 24236842
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optimization of a novel series of potent and orally bioavailable GPR119 agonists.
    Koshizawa T; Morimoto T; Watanabe G; Watanabe T; Yamasaki N; Sawada Y; Fukuda T; Okuda A; Shibuya K; Ohgiya T
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3249-3253. PubMed ID: 28648463
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antidiabetic effects of flavonoids from Sophora flavescens EtOAc extract in type 2 diabetic KK-ay mice.
    Yang X; Yang J; Xu C; Huang M; Zhou Q; Lv J; Ma X; Ke C; Ye Y; Shu G; Zhao P
    J Ethnopharmacol; 2015 Aug; 171():161-70. PubMed ID: 26051831
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents.
    Han J; Huang Y; Chen X; Zhou F; Fei Y; Fu J
    Eur J Med Chem; 2018 Sep; 157():177-187. PubMed ID: 30096651
    [TBL] [Abstract][Full Text] [Related]  

  • 80. TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice.
    Huang S; Ma S; Ning M; Yang W; Ye Y; Zhang L; Shen J; Leng Y
    Metabolism; 2019 Oct; 99():45-56. PubMed ID: 31295453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.